Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Recruiting
Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
2026-526026-40-00· Phase 2/3· Gilead Sciences Inc.· Source
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07711418· Phase 3· Nektar Therapeutics· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510· Phase 3· Dianthus Therapeutics· Source
Recruiting
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881· Phase 3· Rapport Therapeutics Inc.· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· Phase 3· AbbVie· Source
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· Phase 3· Novo Nordisk A/S· Source
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332· Phase 3· Inhibikase Therapeutics· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655· Phase 3· Liquidia Technologies, Inc.· Source
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· Phase 2/3· Corxel Pharmaceuticals Co. Ltd.· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
Multicenter clinical trial to evaluate efficacy and safety of sublingual immunotherapy in patients allergic to house mites, with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma
2023-505918-14-00· Phase 3· Inmunotek S.L.· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· Phase 3· GlaxoSmithKline· Source
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558· Phase 2· Calico Life Sciences LLC· Source
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· Phase 3· Pharmacosmos A/S· Source
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662· Phase 2· Immunovant Sciences GmbH· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· Phase 3· Takeda· Source
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505· Phase 3· AbbVie· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· Phase 3· AbbVie· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Active, not recruiting
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249· Phase 4· GlaxoSmithKline· Source
Recruiting
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
NCT06317805· Phase 4· AOP Orphan Pharmaceuticals AG· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949· Phase 3· AbbVie· Source
Active, not recruiting
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940· Phase 3· Exelixis· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172· Phase 3· H. Lundbeck A/S· Source
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675· Phase 3· H. Lundbeck A/S· Source
Active, not recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029· Phase 3· Merck Sharp & Dohme LLC· Source
Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186· Phase 3· United Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005· Phase 3· Hoffmann-La Roche· Source